Post-transplant diabetes mellitus associated with heart and lung transplant

Kgosidialwa, Oratile; Blake, Kieran; O’Connell, Oisin; Egan, Jim; O’Neill, Jim; Hatunic, Mensud

doi:10.1007/s11845-019-02068-7

Cited by 13 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Risk factors for PTDM included elevated BMI, discharge from the hospital on insulin, and glucose values in the 24 h prior to hospital discharge (121). In an Iranian cohort, 19% had PTDM after heart and lung transplant (122). The OGTT is considered the gold standard test for the diagnosis of PTDM (1 year posttransplant) (114,115,123,124).…”

Section: Screening and Testing For Prediabetes And Type 2 Diabetes Inmentioning

confidence: 99%

2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2021

2020

Diabetes Care

1,945

1,119

View full text Add to dashboard Cite

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

show abstract

Section: Screening and Testing For Prediabetes And Type 2 Diabetes Inmentioning

confidence: 99%

2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2021

2020

Diabetes Care

1,945

1,119

View full text Add to dashboard Cite

show abstract

“…Risk factors for PTDM included elevated BMI, discharge from the hospital on insulin, and glucose values in the 24 h prior to hospital discharge (152). In an Iranian cohort, 19% had PTDM after heart and lung transplant (153). The OGTT is considered the gold-standard test for the diagnosis of PTDM (1 year posttransplant) (143,144,154,155).…”

Section: Screening and Testing For Prediabetes And Type 2 Diabetes In Children And Adolescentsmentioning

confidence: 99%

2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2022

2021

Diabetes Care

1,262

655

View full text Add to dashboard Cite

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc22-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

show abstract

“…Currently, there are no defi nite guidelines regarding DM patient management after HTx with newly developed malignancies. It´s a multidisciplinary problem that requires collaboration between a transplant specialist, an oncologist, and a DM specialist (19). The transplant specialist must perform a thorough screening for the most common malignancies and consider switching their patients to mTOR inhibitors if a malignancy develops.…”

Section: Discusionmentioning

confidence: 99%

Metformin therapy and risk of cancer in patients after heart transplantation

Bedáňová¹,

Horváth²,

Ondrášek³

et al. 2021

BLL

View full text Add to dashboard Cite

BACKGROUND: Diabetes mellitus (DM) and malignancy are recognized among the most common complications increasing mortality in patients after heart transplantation (HTx). Clinical trials have shown a higher risk for different types of tumours in diabetic patients. This risk is potentiated by immunosuppressive therapy in transplant patients. Biguanide metformin has been shown to exhibit anti-tumour activity and we tried to fi nd out whether this effect is valid for heart transplant patients. METHODS: We retrospectively analysed a group of 497 patients, who undergone HTx in our centre between 1998 and 2019. The primary outcome was any malignancy during the 15-year follow-up period and patient's survival. RESULTS: Out of the 497 patients enrolled in the study, 279 (56 %) had diabetes and 52 (19 %) were treated with metformin. Fifteen-year survival in treated patients without malignancy was 93 %, the remainder for the DM patients was 56 %, with survival in non-DM patients being 74 %. Untreated diabetic patients had 4.7 times higher chance of malignancy than those on metformin (p = 0.01). Fifteen-year survival in metformin treated patients was 53 %, in other DM patients 44 %, and in non-DM patients 51 %. CONCLUSION: Our study showed a signifi cantly lower incidence of malignancies in metformin-treated patients and slightly better overall survival (Tab. 2, Fig. 3, Ref. 19).

show abstract

Post-transplant diabetes mellitus associated with heart and lung transplant

Cited by 13 publications

References 21 publications

2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2021

2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2021

2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2022

Metformin therapy and risk of cancer in patients after heart transplantation

Contact Info

Product

Resources

About